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Abstract 
Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged 
by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be 
supported by a subpopulation of stem-like cells termed colon cancer–initiating cell (CCIC), which may also 
confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully 
characterized. To explore this question, we systematically generated CCICs through spheroid cultures of 
patient-derived xenografts of metastatic colorectal cancer. These cultures, termed “xenospheres,” were 
capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus 
operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic 
response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene 
were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were 
sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines 
secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte 
growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR 
inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET 
inhibition, which sensitized the response to EGFR therapy. By showing that RASwtCCICs rely on both EGFR 
and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two 
pathways in the clinical setting. Cancer Res; 74(6); 1857–69. ©2014 AACR. 
 
Introduction 
The survival outcome of patients with colorectal cancer at metastatic stage is improving, thanks to the agents 
such as antibodies (cetuximab and panitumumab) targeting the EGF receptor (EGFR). However, these tumors 
are often intrinsically refractory and those that are sensitive almost invariably relapse, mainly due to 
concomitant genetic alterations that confer EGFR-independent proliferation (reviewed in ref. 1). Such 
alterations include mutations of KRAS, NRAS, and BRAF, as well as amplification of HER2 and MET (2–5). 
A still elusive, but potentially crucial cause of treatment failure is the survival of the so-called “cancer stem 
cells.” Increasing evidence shows that colorectal cancer—as well as other tumors—contains such cells, more 
appropriately defined as cancer-initiating cells (CIC), to emphasize their distinctive operational property of 
driving clonal expansion in xenotransplantation assays (6, 7). Consistently, CICs retain long-term self-renewal 
abilityin vitro, and restore, in vitro and in vivo, a cell hierarchy including both CICs and cells devoid of 
tumorigenic and self-renewal properties (non–CIC). 
Accumulating data indicate that, whereas non–CICs are usually sensitive, CICs are inherently resistant to 
radiochemotherapy, owing to still poorly understood mechanisms that include efficient DNA repair and self-
sustained protection from apoptosis (8–12). The molecular basis of CIC resistance to targeted therapies is 
even less characterized because of the lack of models that integrate CIC genetic features with therapeutic 
responses. 
Besides cell-autonomous genetic factors or functional traits typical of CICs, the tumor microenvironment 
contributes to resistance against targeted therapies as well (reviewed in ref. 13); indeed, stromal-derived 
growth factors can circumvent the proliferative blockade imposed by agents targeting receptor tyrosine kinases 
or their downstream transducers (14–16). The microenvironment could also promote therapeutic resistance at 
the CIC level, by providing factors that may exacerbate intrinsic drug refractoriness, and/or sustain distinctive 
CIC properties such as long-term self-renewal. 
To unveil the mechanisms underlying sensitivity or resistance of colon CICs (CCIC) to targeting agents, we 
generated a model that integrates characterization of CCIC genetic lesions, biological/tumorigenic properties, 
and therapeutic responses in vitro and in vivo. Taking advantage of our ample collection of patient-derived 
xenografts of colorectal cancer liver metastasis (xenopatients) molecularly annotated and characterized for 
their response to EGFR inhibitors (4), we derived and characterized a panel of CCICs (xenospheres) and used 
them to generate secondary tumors in recipient mice (spheropatients). We found that, in consistence with 
clinical data, in the absence of constitutive RAS activation, CCIC proliferation and survival rely on the EGFR 
pathway. However, this dependency could be bypassed by other growth factor receptors, mainly wild-type 
MET activated by a paracrine circuit of hepatocyte growth factor (HGF). Consistently, inhibition of MET could 
empower sensitivity to anti-EGFR therapy. 
 
Materials and Methods 
 
Xenosphere generation from xenopatients 
Animal experimentation was approved by the Italian Ministry of Health and the internal Ethical Committee for 
Animal Experimentation. Cells dissociated from xenopatient tumors (4) were grown in standard stem-cell 
medium, including basal stem cell medium, i.e., DMEM/F-12 (Sigma), 2 mmol/L glutamine (Sigma), penicillin–
streptomycin (EuroClone), N-2 (Life Technologies-GIBCO), 0.4% bovine serum albumin (Sigma), 4 μg/mL 
heparin (Sigma), chemically defined lipid concentrate (Life Technologies-GIBCO), supplemented with human 
recombinant EGF (20 ng/mL; Sigma), and basic fibroblast growth factor (bFGF; 10 ng/mL; Peprotech). 
 
Spheropatient generation and therapy 
Dissociated xenosphere cells (106 cells/mL) were resuspended in a 1:1 mixture of basal stem-cell medium and 
Matrigel (BD Biosciences) and were subcutaneously injected into nonobese diabetic/severe combined 
immunodeficient (NOD/SCID) female mice (Charles River Laboratories) or human HGF knockin SCID mice. 
When tumors reached an average volume of 400 mm3, mice were randomized and treated with 20 mg/kg 
cetuximab (Merck) twice a week, or 50 mg/kg of JNJ-38877605 daily (17), or both agents, or vehicle. Tumor 
size was measured once a week by caliper, and volume was calculated using the formula 4/3(d/2)2D/2, 
where d is the minor and D is the major tumor axis. 
 
Fibroblast conditioned medium 
Primary colorectal cancer specimens were processed as described above and grown in adhesive dishes. 
Fibroblasts were separated from epithelial cells by serial trypsinization. MRC5 fibroblasts were from the 
American Type Culture Collection; human telomerase reverse transcriptase (hTERT) fibroblasts were kindly 
provided by Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, 
(18). Fibroblasts were cultured to confluence and then kept for 24 hours in basal stem-cell medium. Fibroblast 
conditioned medium (FCM) was analyzed with the RayBio Human Cytokine Antibody Array 5 (RayBiotech, 
Inc.). 
 
Flow-cytometric analysis 
Cells (2 × 105) were incubated with the following mouse monoclonal antibodies—anti-CD133/1 (Miltenyi Biotec 
GmbH), anti-MET (R&D Systems Inc.), anti-CD24, and anti-CD44 (both Invitrogen)—and were analyzed in a 
CyAn ADP (Dako Cytomation). 
Cell viability and apoptosis assays 
Cells were plated at clonal density (10 cells/μL) in basal stem-cell medium. Growth factors, cetuximab (10 
μg/mL), JNJ-38877605 (0.5 μmol/L), or gefitinib (0.5 μmol/L) were added at day 0. ATP production and 
caspase-3/7 activity were measured using CellTiter-Glo (Promega) and Caspase-Glo 3/7 Assay (Promega), 
respectively, and a GloMax 96 Microplate Luminometer (Promega). 
 
Western blot analysis 
Immunoblottings were analyzed with the following antibodies: mouse monoclonal anti-MET (DL21; ref. 19), 
goat polyclonal anti-HGF (R&D Systems), rabbit monoclonal anti-EGFR, rabbit anti–phospho-ERK1/2 
(Thr202/204), rabbit anti-ERK1/2, rabbit anti–phospho-Akt (Ser473), rabbit anti-Akt, rabbit anti–phospho-S6 
(Ser235/236), rabbit anti-S6 (all Cell Signaling Technology), and rabbit anti–phospho-EGFR (Tyr1068; 
Abcam). Mouse monoclonal anti-Hsp70 (Santa Cruz Biotechnology) and anti-vinculin (Sigma-Aldrich) 
antibodies were used as controls of equal protein loading. 
 
Immunohistochemistry 
Tumor sections were formalin-fixed, paraffin-embedded, processed according to the standard procedures, and 
analyzed with the following antibodies: anti–phospho-S6 rabbit monoclonal (Ser235/236; Cell Signaling 
Technology) and anti–phospho-ERK1/2 rabbit monoclonal (Thr202/204; Cell Signaling Technology). 
 
Statistical analysis 
Results were expressed as mean ± SEM. Statistical significance was evaluated using two-tailed 
Student t tests. P < 0.05 was considered statistically significant. Statistical analysis of HGF expression in a 
publicly available dataset [Gene Expression Omnibus (GEO) dataset GSE5851; ref. 20] was performed by the 
Fisher exact test on data extracted from KRASwt patients, taking the 75th percentile as threshold and 
comparing patients with reported progressive disease versus those with complete/partial response and stable 
disease. 
For more detailed methods, see Supplementary Experimental Procedures. 
 
Results 
 
Xenospheres retain genetic mutations of xenopatients 
To obtain CCICs, xenopatient tumors were dissociated and selected in standard stem-cell medium, thus 
establishing sphere cultures, which, as previously shown, are enriched in stem/progenitor cells (11, 21, 22). To 
specify their origin from xenopatients rather than from fresh surgical specimens, these spheres were named 
“xenospheres” (Supplementary Fig. S1A). Eight distinct xenosphere lineages were established from as many 
xenopatients and these displayed the ability for long-term self-propagation in vitro (see below). Together with 
their respective xenopatient tumors, xenospheres underwent analysis of gene alterations typically associated 
with colorectal cancer resistance to EGFR-targeted therapy (KRAS, NRAS, BRAF, and PIK3CA gene 
mutations; HER2 andMET gene amplifications). Xenospheres retained the same lesions detected in the 
matched xenopatients (Supplementary Table S1), allowing grouping in two main subsets: (i) xenospheres 
lacking alterations of KRAS, NRAS, BRAF, HER2, or MET, hereafter indicated as RASwt (M016, M049, M195, 
and M199); and (ii) xenospheres harboring a mutated KRAS gene—invariably at residue G12—hereafter 
indicated as RASmut (M119, M126, M138, and M211). Although the efficiency of xenosphere derivation was 
relatively low (10%–15%), the frequency of KRAS mutation was similar in xenospheres, xenopatients, and 
patients, ruling out a selection bias for this mutation. Mutational analysis was extended to APC gene hotspots, 
and, again, concordant frequency among xenospheres, xenopatients, and human patients was observed 
(Supplementary Table S1). 
 
 
 
Xenospheres generate tumors that recapitulate morphology and therapeutic sensitivity of the original 
xenopatients 
To assess the tumorigenic potential of xenospheres, 105 cells were injected subcutaneously into NOD/SCID 
mice to produce “spheropatients” (100% engraftment efficiency; Supplementary Fig. S1A). Spheropatient 
tumors reproduced the same morphology as the corresponding xenopatients (Fig. 1A), and thus as the original 
tumor. This confirms the histogenetic and pseudodifferentiating ability of CICs (6, 7, 23, 24) and indicates that 
tumors from xenospheres properly recapitulate intra- and intertumor heterogeneity. From spheropatients, 
secondary xenospheres could be rederived, which retained the same in vitro properties and tumorigenicity of 
the primary xenosphere, namely the ability to sustain serial transplantation (Supplementary Fig. S1A). 
 
 
Figure 1. 
Xenospheres generate tumors that recapitulate morphology and therapeutic sensitivity of the original xenopatients. A, tumor sections 
(hematoxylin and eosin staining). Scale bar, 100 μm. B, tumor growth curves. Graphs, tumor volume fold increase/decrease versus 
day 0 ± SEM (n = 6 for M016 and M049; n= 3 for M195, M119, M126, and M138; *, P < 0.05). 
 
To ascertain whether the therapeutic responses of the original tumors were retained, spheropatients were 
treated with the anti-EGFR antibody cetuximab. Like the matched xenopatients, RASwt spheropatients M016, 
M049, and M195 underwent tumor regression (Fig. 1B and Supplementary Table S2), whereas 
RASmut spheropatients M119, M126, and M138 experienced tumor progression similar to controls (Fig. 1B). Of 
note, CCICs of spheropatient M016 (as well as the bulk of the corresponding xenopatient) exhibited 
aPIK3CA exon 20 mutation (Supplementary Table S1), whose role as resistance biomarker is still debated 
(25). In our context, both M016 xenopatient and spheropatient responded to cetuximab with evident tumor 
shrinkage (4), confirming their concordance. 
 
Xenospheres display in vitro properties and markers of CCICs 
CCICs are defined not only by the ability to regenerate tumors with the same morphology (and therapeutic 
response) as the original tumors, but also by the ability to self-renew in vitro and to switch toward growth arrest 
and differentiation in appropriate culture conditions (24). Accordingly, xenospheres could be propagated in 
standard stem-cell medium for more than 60 passages, without alteration of proliferative or tumorigenic 
potential. Conversely, when cultured in prodifferentiating conditions, xenospheres ceased to grow and died, 
although RASmut survived longer than RASwt xenospheres (Supplementary Fig. S1B and data not shown). 
Xenospheres were then analyzed for expression of markers previously used to isolate and characterize 
CCICs, such as CD133, CD44, and CD24 (24). Flow-cytometric analysis revealed high and consistent CD24 
expression and lower and more heterogeneous CD44 expression (Fig. 2A). Unexpectedly, CD133 expression, 
previously used to prospectively isolate CCIC from primary colorectal cancer (6, 7), was very heterogeneous 
within and among the remaining xenospheres. This is not surprising, as in metastatic colorectal cancer both 
CD133+ and CD133− cells display tumor-initiating ability (26). 
 
 
 
 
Figure 2. 
Xenospheres display in vitromarkers of CCICs and different growth factor (GF) requirements depending on RAS mutational status. 
A, flow-cytometric analysis of CD24, CD44, and CD133 in xenospheres. B, growth curves of xenospheres. Graphs, relative viability 
increase versus day 0 ± SEM (n = 3; *, P < 0.05). C, cell viability of xenospheres kept in basal stem-cell medium either alone (no 
growth factors) or with the indicated growth factors for 6 days. Columns, relative cell viability versus no growth factors ± SEM (n = 3; 
*, P < 0.05). 
Xenospheres were also analyzed for expression of receptors activated by ligands present in standard stem-cell medium, including 
EGFR family members (EGFR, HER2, and HER3), and FGFR2. Transcripts for the four receptors were significantly expressed in all 
xenospheres (Supplementary Fig. S1C) as was EGFR protein, albeit at variable levels (Supplementary Fig. S1D). 
 
Proliferation of RASwt but not RASmut xenospheres requires exogenous growth factors 
In growth curve assays, representative RASwt xenospheres (M016 and M049) proliferated only in the presence 
of exogenous growth factors, that is, EGF-bFGF, whereas representative RASmut xenospheres (M126 and 
M138) displayed the same proliferation rate irrespective of exogenous growth factors (Fig. 2B), even though 
EGF (stem-cell medium) could induce EGFR phosphorylation (Supplementary Fig. S1E). Similarly, after 
dissociation and embedding in soft agar, RASwt cells formed spheres only in the presence of exogenous 
growth factors, whereas RASmut cells grew even in their absence (Supplementary Fig. S1F). 
Next, the xenosphere proliferative response to individual EGF or bFGF was assessed. All four 
RASwt xenospheres were significantly stimulated by EGF; three of them (M016, M49, and M195) were 
stimulated also by bFGF alone, although less efficiently than by EGF, and responded to the EGF–bFGF 
combination with an additive effect (Fig. 2C). Conversely, proliferation of RASmut xenospheres was not further 
increased by either EGF or bFGF, with the (partial) exception of M119 (Fig. 2C). 
 
Xenosphere response to EGFR inhibition hinges on RAS mutation and on paracrine/autocrine EGF signaling 
We then investigated whether cetuximab could block proliferation and induce apoptosis of CCICs in vitro. As 
expected, in representative RASmut xenospheres M126 and M138, cetuximab did not affect cell viability (Fig. 
3A) or apoptosis (Fig. 3B), irrespective of the presence of growth factors. However, although cetuximab 
induced a therapeutic response in RASwt xeno- and spheropatients (see above; Fig. 1B; ref. 4), it did not 
significantly affect proliferation or apoptosis of the corresponding RASwt xenospheres cultured in standard 
stem-cell medium (Fig. 3C and D). This could be explained by the presence of (i) an excess EGF (20 ng/mL) 
that likely outcompeted the effective dose of the antibody (10 μg/mL) for binding the EGFR receptor 
extracellular domain (5, 27), and (ii) bFGF (10 ng/mL) that could compensate for EGFR inhibition in sustaining 
viability. We then verified that the minimal EGF concentration required to achieve a plateau proliferative effect 
in RASwt xenospheres was as low as 0.2 ng/mL (Supplementary Fig. S2A); at this EGF concentration (and up 
to 2 ng/mL), cetuximab potently impaired viability of representative RASwt xenospheres (Fig. 3E), in 
accordance with the in vivo data. In dose–response experiments, we also showed that bFGF concentrations 
higher than those present in the standard stem-cell medium (at least 20 ng/mL) could significantly, although 
partly, restore viability and protect RASwt xenospheres from apoptosis induced by cetuximab (Fig. 3F and G). 
 
 
 
 
Figure 3. 
Xenosphere response to EGFR inhibition hinges on RAS mutation and on paracrine/autocrine EGF signaling. A–D, cell viability (A 
and C) and caspase-3/7 activity (B and D) assays of xenospheres kept for 4 days in standard (EGF-bFGF) or basal [no growth 
factors (GF)] stem-cell medium. Caspase activity was normalized versus CellTiter-Glo values. Columns, relative viability or caspase 
activity versus xenospheres kept in EGF-bFGF and vehicle of a representative experiment ± SEM (n = 3; *, P < 0.05). E, F, and G, 
cell viability (E and F) or caspase-3/7 activity (G) of xenospheres kept for 4 days in basal stem-cell medium alone (no growth factors) 
or with increasing doses of growth factors (ng/mL). Columns, relative viability or caspase activity versus xenospheres kept with no 
growth factor of a representative experiment ± SEM (n = 3; *, P < 0.05). 
 
Interestingly, when cultured without growth factors (Fig. 3C and D), RASwt xenospheres exhibited different 
basal viability and apoptotic rates, as well as different sensitivity to EGFR blockade. M016 and M199 displayed 
self-sustained viability and low levels of apoptosis, but were extremely sensitive to EGFR inhibition (Fig. 3C 
and D). At variance, M049 and M195 kept in the absence of growth factors were poorly viable and irreversibly 
poised to apoptosis, attitudes that were unaffected by cetuximab (Fig. 3C and D). The behavior of M016 and 
M199 was explained by EGF autocrine expression (Supplementary Fig. S2B), which, on one side, could 
sustain viability even in the absence of exogenous growth factors, and, on the other side, likely sensitized 
CCICs to EGFR inhibition. Results were supported by the use of gefitinib, an alternative EGFR-specific small-
molecule inhibitor (Supplementary Fig. S2C; ref. 28). 
Taken together, these experiments indicate that EGFR inhibition blocked proliferation and induced apoptosis 
of RASwt CCIC. The in vitro response to cetuximab was masked by the standard experimental conditions used 
to grow xenospheres (excess EGF); however, response could be restored by lowering exogenous EGF 
concentration to doses sufficient to fully sustain cell proliferation and survival. 
Xenosphere proliferation and resistance to EGFR inhibition are sustained by fibroblast-derived HGF 
Recent reports highlighted that stromal-derived cytokines mediate resistance to targeted therapies (16). Our 
observation that growth of RASwt CCICs is additively sustained by EGF and bFGF suggests that one or more 
such growth factors might compensate for the interception of EGFR signaling by cetuximab. 
Colorectal cancer–associated fibroblasts (CAF) are known to secrete several growth factors, cytokines, and 
chemokines (29, 30). To investigate the CAF ability to sustain xenosphere propagation, a primary culture of 
CAFs derived from a colorectal cancer sample and two human fibroblast cell lines (MRC5 and hTERT; ref. 18) 
were used to produce FCM. These were analyzed by multiplex cytokine arrays, revealing high amounts of 
interleukin (IL)-6, IL-8, Rantes, Gro-α, and HGF, but negligible quantities of EGF and FGFs (Fig. 4A). 
 
Figure 4. 
Xenosphere proliferation and cetuximab resistance are sustained by fibroblast-derived HGF. A, cytokine array of conditioned media 
(CM), produced from human fibroblast cell lines MRC5 and hTERT or freshly isolated CAFs at passage 3 (p3) or 9 (p9). B, cell 
viability assay of xenospheres cultured in basal stem-cell medium [no growth factors (GF)] or in the same conditioned media 
analyzed in A, and treated with JNJ-38877605 (0.5 μmol/L) or cetuximab (10 μg/mL), or equal volume of vehicle for 4 days. 
Columns, relative cell viability versus xenospheres kept in no growth factors ± SEM (n = 3; *, P < 0.05). C, micrographs 
(magnification, ×100) of xenospheres cocultured with hTERT and treated as above. Cell viability (D) and caspase-3/7 activity (E) of 
xenospheres kept in basal (no growth factors) or standard (EGF-bFGF) stem-cell medium or in the presence of MRC5-CM or 
hTERT-CM and treated as above. Columns, relative viability and caspase activity versus xenospheres kept in EGF-bFGF and 
vehicle of a representative experiment ± SEM (n = 3; *, P < 0.05). 
 
Using the representative RASwt xenosphere M049, we noticed that FCM from different fibroblast cell lines 
induced cell proliferation proportionally to the amount of HGF secreted. Indeed, the FCM from senescent 
CAFs (p9), where most cytokines were still abundant, but HGF was significantly reduced, did not induce 
proliferation (Fig. 4A and B). At odds, changes in contents of other cytokines (e.g., IL-6, Rantes, or Gro-α) did 
not correlate with changes in xenosphere viability (Fig. 4A and B). Moreover, FCM-induced proliferation was 
completely blocked by JNJ-38877605, a specific inhibitor of the HGF receptor, MET (Fig. 4B; ref. 17), or by the 
anti-MET monovalent antibody DN30-FAB (Supplementary Fig. S3A; ref. 31). Importantly, FCM not only 
sustained the growth of xenospheres, but it also protected them from cetuximab (Fig. 4B). Similarly, coculture 
with hTERT fibroblasts also sustained xenosphere growth and viability, which were impaired after the addition 
of JNJ-38877605, but not of cetuximab (Fig. 4C). 
The proliferative effect of FCM, as well as FCM contribution to resistance against EGFR inhibition, was 
confirmed on RASwt M016, M049, and M195; in the presence of FCM, cetuximab and gefitinib did not affect 
viability (Fig. 4D and Supplementary Fig. S3B), nor did they promote caspase activation (Fig. 4E and 
Supplementary Fig. S3C). Conversely, JNJ-38877605 completely blocked proliferation and induced apoptosis 
(Fig. 4D and E and Supplementary Fig. S3B and S3C), attesting that HGF mediates the protective activity of 
FCM. Interestingly, in RASwt M199, FCM promoted viability, but inhibition by JNJ-38877605 was attenuated 
(Supplementary Fig. S3B and S3C) likely by the expression of a strong EGF autocrine loop (Supplementary 
Fig. S2B). Consistently, this xenosphere maintained sensitivity to EGFR inhibitors (Supplementary Fig. S3B 
and S3C). 
The role of HGF in sustaining CCIC proliferation was further confirmed by supplying purified HGF as a single 
growth factor (Fig. 5A). RASwt M016 and M049 were treated with cetuximab in the presence of HGF or IL-8, 
another cytokine particularly abundant in FCM (Fig. 4A). HGF, but not IL-8, significantly protected both 
xenospheres from cetuximab, by preserving cell viability and inhibiting apoptosis (Fig. 5B and C). Protection 
was likely mediated by activation of mitogen—activated protein kinase (MAPK) and AKT pathways, which 
remained high when HGF was supplied together with cetuximab, and was extinguished when the MET 
inhibitor was also added (Fig. 5D). Similar to our observations with FCM, protection against cetuximab by 
purified HGF was dose-dependent (Supplementary Fig. S4A). 
 
 
 
Figure 5. 
HGF activity and MET expression in xenospheres. A, cell viability of xenospheres kept in basal stem-cell medium either alone [no 
growth factors (GF)] or with HGF (20 ng/mL) for 6 days. Columns, the relative viability versus no growth factors ± SEM (n = 3; *, P< 
0.05). B and C, cell viability (B) and caspase-3/7 activity (C) assays of M016 and M049 xenospheres kept for 4 days in basal stem-
cell medium alone (no growth factors) or supplemented with EGF (0.2 ng/mL) and increasing doses of HGF (0.2, 20, and 50 ng/mL), 
and treated either with cetuximab (10 μg/mL) or equal volume of vehicle. Columns, the relative viability and caspase activity versus 
no growth factors and vehicle of a representative experiment ± SEM (n= 3; *, P < 0.05). D and E, Western blot analysis of total 
protein extracts (D) from M049 xenospheres cultured in basal stem-cell medium supplemented with combinations of EGF (0.2 
ng/mL) or HGF (20 ng/mL), treated with cetuximab (10 μg/mL) or JNJ-38877605 (0.5 μmol/L) as indicated, or from the indicated 
xenospheres or their differentiated derivatives (serum; E). F, flow-cytometric analysis of MET. 
 
MET expression in xenospheres 
Significant expression of MET was verified in all xenospheres by Western blot analysis (Fig. 5E) and flow 
cytometry (Fig. 5F). As an exception, among RASwt xenospheres, M199 displayed lower levels of MET and, 
consistently, weaker proliferative response to HGF (Fig. 5A). Low MET expression also contributed to explain 
why this xenosphere was poorly sensitive to MET inhibitors when grown in FCM (Supplementary Fig. S3B and 
S3C). In RASmut xenospheres, which also expressed high levels of MET, HGF stimulated MET activation 
(Supplementary Fig. S4C), but did not increase their autonomous proliferation rate (not shown). Interestingly, 
in all xenospheres cultured in prodifferentiating conditions, except in RASmut M126, MET protein expression 
decidedly decreased (Fig. 5E), indicating preferential association of MET expression with the stem/progenitor 
status. Notably, serum-induced differentiation affected EGFR expression randomly, with reduced protein levels 
in three xenospheres (M016, M199, and M138) and increased levels in the remaining five (M049, M195, 
M119, M126, and M211; Fig. 5E). 
 
RASwt spheropatients display enhanced response to combined EGFR and MET inhibition 
Data obtained in vitro support the hypothesis that HGF secretion by CAFs provides a mechanism of CCIC 
primary resistance to cetuximab, which can be counteracted by MET inhibition. Consistently, we observed that 
HGF expression in tumors of patients who progressed on cetuximab was significantly higher than that of 
responders, as assessed by analyzing publicly available gene expression datasets of human 
KRASwt metastatic colorectal cancers annotated for response to cetuximab monotherapy (Fig. 6A; ref. 20). 
 
 
 
 
 
Figure 6. 
RASwt spheropatients display enhanced response to combined EGFR and MET inhibition. A, heatmap showing preferential 
association of HGF expression with progressive disease (PD) rather than complete response (CR) or partial response (PR) or stable 
disease (SD) in patients treated with cetuximab as monotherapy. Fisher exact test = 0.0281. B and C, growth curves (log scale) of 
tumors generated by M049 expressing a HGF autocrine loop (B) or by parental M049 injected in mice expressing human HGF 
(hHGFKi; C) and treated as indicated. Graphs, tumor volume increase versus day 0 ± SEM. (n = 5; *, P < 0.05). D, 
immunohistochemical analysis with anti-pERK (pERK) or anti-pS6 (pS6) antibodies of tumor sections derived from M049-HGF 
spheropatients treated as indicated in B. Scale bar, 100 μm. E, long-term tumor growth curves (log scale) of M049-HGF 
spheropatients. Blue and red lines, treatments started at day 0. Black and gray lines, arrows indicate when cetuximab was added. 
Graphs, tumor volume increase versus day 0 ± SEM (n = 3; *, P < 0.05). F, immunohistochemical analysis with anti-pERK or anti-
pS6 antibodies of histologic tumor sections derived from M049-HGF spheropatients treated as indicated in D. Scale bar, 100 μm. 
 
The efficacy of MET inhibitors cannot be assessed in a classical xenograft model, as murine HGF does not 
activate the human MET receptor (32, 33). Consistently, M049 spheropatient did not respond to treatment with 
JNJ-38877605 as a single agent (as previously observed in RASwt xenopatients; ref. 34), or in combination 
with cetuximab (Supplementary Fig. S5A). We thus generated two experimental settings to include human 
HGF in the murine tumor microenvironment. First, M049 xenospheres were transduced with a lentiviral 
construct expressing the human HGF gene (M049-HGF) to induce an autocrine loop (Supplementary Fig. 
S5B). This loop was functional, as shown by administration of JNJ-38877605, which decreased viability of 
M049-HGF, and, in the presence of EGF, increased their sensitivity to cetuximab (Supplementary Fig. S5C 
and S5D). Spheropatients were then obtained by subcutaneous injection of M049-HGF into NOD/SCID mice, 
and treated with placebo, cetuximab, JNJ-38877605, or both inhibitors, for 6 weeks. MET inhibition alone 
slightly, but significantly, delayed tumor growth, although without inducing regression or stabilization. On the 
contrary, cetuximab caused a 70% tumor regression that stabilized after 3 weeks. Interestingly, the 
concomitant administration of cetuximab and JNJ-38877605 resulted in more pronounced tumor regression, 
which continued up to 6 weeks of treatment, reaching 90% (Fig. 6B). 
In the second experimental setting, mice were genetically engineered by replacing the endogenous Hgf gene 
with the human gene (hHGF-Ki), used as recipients of parental M049 xenospheres, and treated as above. In 
this case, JNJ-38877605 was ineffective as a single agent, but enhanced the rate of tumor shrinkage when 
combined with cetuximab, again inducing up to 90% regression after 6 weeks (Fig. 6C). 
As shown by immunohistochemistry of sections from tumors formed by M049-HGF xenospheres, JNJ-
38877605 modestly affected the MAPK and AKT pathways, while cetuximab inhibited completely the MAPK 
and only partially the AKT pathway. Combination of the two inhibitors effectively impaired both signal 
transduction pathways (Fig. 6D), according to in vitro findings (Fig. 5D). 
To assess long-term therapeutic outcomes, M049-HGF spheropatients were treated up to 6 months with 
cetuximab and JNJ-38877605, alone or in combination (Fig. 6E), as above. In these experiments, the groups 
initially treated with vehicle or JNJ-38877605 alone started to receive cetuximab when tumors reached a 
volume of 1,400 or 1,300 mm3, respectively. By this strategy, we could monitor the consequences of delayed 
cetuximab administration in mice that were either naïve for any inhibitor or “primed” by prior MET inhibition. 
Tumors treated with cetuximab alone from the beginning experienced a maximum regression of 70% that 
stabilized after 6 weeks and, at 12 weeks, started to display a slight but continuous trend to regrowth, 
regaining 40% of the baseline volume after 24 weeks. Mice treated with the two inhibitors from the beginning 
showed a decidedly more pronounced tumor regression than mice treated with cetuximab alone, reaching a 
maximum 94% tumor shrinkage after 9 weeks, which stabilized without any statistically significant change until 
24 weeks. The outcomes of the groups with delayed administration of cetuximab were comparable with the 
corresponding “early” treatment groups (Supplementary Table S3); tumors that received delayed cetuximab 
monotherapy reached a maximum 75% regression 4 weeks after treatment initiation, and, at the end of the 
experiment (17 weeks after treatment initiation), regained 58% of the baseline volume. Tumors initially treated 
with JNJ-38877605 and experiencing delayed addition of cetuximab displayed continuous regression, reaching 
90% reduction of their maximum volume (Fig. 6E). 
Consistently, tumors explanted after 6 months of treatment with cetuximab alone exhibited basally 
(re)activated MAPK and AKT pathways, whereas tumors treated with both inhibitors did not show any sign of 
pathway activity (Fig. 6F). Moreover, tumors treated with both inhibitors showed signs of increased 
pseudodifferentiation, such as increased stromal density, and reduced epithelial cellularity, with adenomatous 
phenotype (Fig. 6F) and increased expression of cytokeratin 20 (Supplementary Fig. S6A). Interestingly, 
tumors treated with both inhibitors showed decreased expression of stem-cell markers such as LGR5 and β-
catenin, as well as the corresponding xenospheres treated in vitro showed decreased expression of CD24, 
CD133, CD44, and MET (Supplementary Fig. S6A and S6B). 
 
 
Discussion 
Over decades, cell lines contributed to unravel the genetic basis of cancer pathogenesis and to identify 
therapeutic targets. Nevertheless, their validity for the preclinical screening of anticancer drugs has been 
challenged (reviewed in refs. 35, 36). Indeed, cancer cell lines may fail to recapitulate the overall features of 
the original tumor, because, after the several in vitro passages required to achieve immortalization, they might 
have genetically drifted and lost differentiation plasticity (37). 
The quest for cells maintaining the genetic and histogenetic properties of the original tumors has led to tumor 
“spheres,” primary cultures established by a protocol initially set up for neural stem cells (38), and later 
successfully applied to several tumor tissues, including colorectal cancer (7, 11, 23, 24). These cells display 
the operational properties of cancer stem cells, or CICs. Indeed, they retain long-term self-renewal ability in 
vitro, and, when implanted in immunocompromised mice, form tumors almost indistinguishable from the 
originals (7, 37). Notably, tumor spheres retain the genetic make-up of the original cancer far more faithfully 
than standard cell lines (37); thus, regardless of their “stem” properties, they should be more suitable than cell 
lines to identify the mechanisms responsible for sensitivity and resistance to molecular cancer therapeutics. 
Spheres obtained from colorectal cancer, or “colospheres,” were used to demonstrate CIC resistance to 
conventional therapies (12); however, to our knowledge, little has been done so far to characterize their 
genetic profiles, and to relate them to response to targeted therapies. 
In this work, from human colorectal cancer metastases xenografted in mice, the so-called “xenopatients” (4), 
we derived spheres named “xenospheres.” Colorectal cancer xenopatients allowed (i) to reproduce the 
therapeutic response to anti-EGFR antibodies observed in human patients, (ii) to validate negative predictors 
of response, such as mutations in RAS pathway genes, (iii) to discover HER2 amplification as a novel 
mechanism of primary resistance, and (iv) to validate HER2 as an effective therapeutic target in combination 
with EGFR inhibitors (4). More recently, xenopatients contributed to demonstrate that amplification of 
the MET oncogene is a mechanism of both primary and secondary resistance to anti-EGFR therapies (3). 
Taking advantage of data available in the original corresponding patients and xenopatients, here we show that 
xenospheres (i) retain the same genetic lesions of the tumor of origin and (ii) generate tumor xenografts 
(spheropatients) that recapitulate the histologic heterogeneity of the corresponding xenopatients (and thus of 
the corresponding patients). We also show that (iii) the spheropatient response to the anti-EGFR antibody is 
comparable with the response observed in the corresponding xenopatients, in accordance with the mutational 
status of KRAS. We, thus, conclude that xenospheres are a reliable, molecularly annotated, in vitro model of 
CCICs, able to retain from the tumor of origin, and pass to a secondary tumor (spheropatient), the genetic 
determinants of therapeutic response. 
We then confirmed, for the first time in CCIC, the relevance of the KRAS gene status for proliferation and 
survival. Indeed, xenospheres harboring a KRAS mutation self-sustain their growth and are insensitive to 
exogenous growth factors. Conversely, xenospheres with wild-type KRAS, NRAS, and BRAF cannot grow and 
survive unless supplied with exogenous growth factors. Although the number of cases examined was limited, 
we show that RASwt xenospheres are exquisitely sensitive to EGF; indeed, they proliferate at an EGF molar 
concentration one log lower than that required for other growth factors such as FGF or HGF. In some cases, 
xenospheres express EGF autocrine loops able to maintain basal survival signals, although insufficient to 
sustain autonomous proliferation. We therefore show that the response of the original xenopatients (and 
patients) to EGFR inhibition is rooted in CCICs: if RAS pathway genes are intact, EGFR inhibitors can stop 
tumor growth by hitting the tumorigenic cell subpopulation. 
However, we also found that, in this subpopulation, EGFR may be the dominant but not the unique regulator of 
proliferation. The HGF receptor MET was expressed in all xenospheres, and, unlike EGFR, it was 
downregulated in their in vitro differentiated derivatives, suggesting a specific association of MET expression 
with—and possibly a specific function within—the stem/progenitor compartment. Consistently, we and others 
have recently reported that MET is expressed in glioblastoma stem cells and promotes their self-renewal (39–
41). Concerning colorectal cancer, it was previously shown that HGF can sustain the WNT self-renewal 
pathway (42, 43). Yet, the ability of HGF to sustain long-term CCIC proliferation was unknown. We show here 
that HGF can promote RASwt CCIC proliferation, and that inherent expression of the wild-type MET gene in 
these cells is a factor of primary resistance to anti-EGFR therapy, a finding with salient implications for 
colorectal cancer pathogenesis and therapy. 
Although MET amplification likely represents a rare mechanism of primary resistance to EGFR inhibition (1% 
of xenopatients; ref. 3), intrinsic expression of wild-type MET, together with physiologic secretion of HGF by 
CAFs, may provide a more widespread mechanism. Indeed, we show that, in the microenvironment generated 
by conditioned media or cocultures of CAFs, HGF is so abundant that it may take the lead over other growth 
factors, including EGF, to regulate CCIC proliferation and survival. As a result, in the presence of excess HGF, 
MET inhibition, but not EGFR inhibition, is sufficient to stop the growth of CCIC. Primary resistance provided 
by HGF may be relevant in human patients, as suggested by our analysis of data from patients with metastatic 
colorectal cancer who received cetuximab as monotherapy (20); indeed, high HGF expression in 
KRASwt tumors associates with poor response to cetuximab. 
The ability of MET to support CCIC growth in vitro prompted us to reconsider previous results showing that, in 
xenopatients, MET inhibition failed to block metastatic colorectal cancer featuring wild-type MET (34). Indeed, 
those experiments were performed in regular immunocompromised mice (NOD/SCID), where murine HGF 
exerts negligible effects, as it does not cross-react with human MET (32, 33). To better evaluate the 
contribution of HGF to CCIC tumorigenicity, we generated two RASwt spheropatient models by engineering 
either the xenospheres or the mice to express human HGF. In these models, MET inhibition alone could not 
induce significant tumor regression; however, when it was combined with EGFR inhibition, regression was 
boosted and stabilized for long time, delaying, and possibly preventing, tumor relapse. Importantly, the 
combined treatment resulted in decreased expression of cancer stem cell markers, in vitro and in vivo, 
indicating empowered targeting of CCICs. 
Previous studies have shown that HGF sustains resistance against EGFR inhibition in cell lines (44, 45). We 
now suggest that concomitant inhibition of the two targets—MET and EGFR—hits CCICs that feature defined 
genetic traits such as wild-type RAS pathway genes. This approach may help to prevent resistance to targeted 
therapies and lead to a virtually complete and durable tumor regression. 
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